{"id":56054,"date":"2026-01-12T10:35:13","date_gmt":"2026-01-12T09:35:13","guid":{"rendered":"https:\/\/editing.capitalmind.com\/?post_type=deals&p=56054"},"modified":"2026-01-12T17:55:18","modified_gmt":"2026-01-12T16:55:18","slug":"cession-groupe-suisse-leader-en-oncologie-a-hirslanden","status":"publish","type":"deals","link":"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/","title":{"rendered":"Cession d’un groupe suisse leader en oncologie \u00e0 Hirslanden"},"content":{"rendered":"\n

Investec a conseill\u00e9 les propri\u00e9taires de la clinique d’oncologie KHO (Klinik f\u00fcr H\u00e4matologie und Onkologie Hirslanden Z\u00fcrich<\/em>) et de l’Onkozentrum Z\u00fcrich<\/em> dans le cadre de leur cession respective \u00e0 la famille propri\u00e9taire du groupe de cliniques priv\u00e9s Hirslanden.<\/strong><\/p>\n\n\n\n

A propos du deal<\/h2>\n\n\n\n

Investec a agi en tant que conseil financier exclusif de la Klinik f\u00fcr H\u00e4matologie und Onkologie Hirslanden Z\u00fcrich et de l’Onkozentrum Z\u00fcrich dans le cadre de la cession conjointe de leur participation majoritaire \u00e0 la famille propri\u00e9taire du groupe Hirslanden.<\/p>\n\n\n\n

Ces deux institutions suisses de premier plan dans le domaine du traitement du cancer offrent ensemble une gamme compl\u00e8te de services en oncologie et en h\u00e9matologie, y compris des options de diagnostic et de traitement hautement sp\u00e9cialis\u00e9es et \u00e0 la pointe de la technologie. Avec une \u00e9quipe d’environ 20 oncologues m\u00e9dicaux hautement exp\u00e9riment\u00e9s (dont beaucoup sont des leaders d’opinion internationaux dans leur domaine), plus de 11 000 traitements sont effectu\u00e9s chaque ann\u00e9e dans cinq sites du canton de Zurich pour tous les types de cancer.<\/p>\n\n\n\n

Hirslanden est le plus grand groupe de cliniques priv\u00e9es en Suisse avec 17 h\u00f4pitaux, dont beaucoup disposent d’un service d’urgence. Il g\u00e8re \u00e9galement 5 centres de chirurgie ambulatoire, 19 instituts de radiologie et 6 instituts de radioth\u00e9rapie. Le groupe compte 2 651 m\u00e9decins partenaires et 11 146 employ\u00e9s.<\/p>\n\n\n\n

Le partenariat strat\u00e9gique entre les deux centres d’oncologie et Hirslanden permettra d’offrir des soins m\u00e9dicaux de haute qualit\u00e9 tout en mettant l’accent sur la continuit\u00e9 entrepreneuriale : en tant que coactionnaires, les m\u00e9decins propri\u00e9taires continueront \u00e0 assurer le succ\u00e8s m\u00e9dical et entrepreneurial de leurs centres.<\/p>\n\n\n

\n
\n
\n \n
\n \u201c\u201d<\/span>\n\n

\u201cLa collaboration avec l’\u00e9quipe M&A d’Investec a \u00e9t\u00e9 tr\u00e8s positive. L’\u00e9quipe a pr\u00e9par\u00e9 et ex\u00e9cut\u00e9 le projet avec un grand professionnalisme et une grande efficacit\u00e9, soutenant les actionnaires des deux soci\u00e9t\u00e9s avec un engagement sans faille \u00e0 toutes les \u00e9tapes du projet. Gr\u00e2ce \u00e0 leur expertise, leurs ressources humaines et leur approche ax\u00e9e sur les r\u00e9sultats, m\u00eame dans des situations complexes, nous avons pu r\u00e9aliser une transaction id\u00e9ale avec un partenaire strat\u00e9giquement tr\u00e8s pertinent. Nous avons beaucoup appr\u00e9ci\u00e9 la collaboration personnelle et professionnelle avec Investec.\u201d<\/p>\n<\/div> \n\n – Prof. Dr. med. Christoph Renner, copropri\u00e9taire de KHO Hirslanden Z\u00fcrich AG et d'Onkozentrum Z\u00fcrich AG<\/cite>\n <\/blockquote>\n <\/div>\n <\/div>\n<\/section>\n\n\n\n

Notre r\u00f4le<\/h2>\n\n\n\n

Investec a conseill\u00e9 les propri\u00e9taires des deux centres d’oncologie tout au long du processus de M&A jusqu’\u00e0 la conclusion r\u00e9ussie de la transaction, notamment :<\/p>\n\n\n\n

    \n
  • Pr\u00e9paration du Business plan<\/em> et des supports marketing ;<\/li>\n\n\n\n
  • Analyse d\u00e9taill\u00e9e de l’impact du Tardoc (syst\u00e8me suisse de remboursement des soins de sant\u00e9) ; <\/li>\n\n\n\n
  • Identification des acqu\u00e9reurs potentiels (strat\u00e9giques et financiers) ;<\/li>\n\n\n\n
  • Approche du march\u00e9 et mise en place d’un processus de vente concurrentiel ;<\/li>\n\n\n\n
  • Pr\u00e9paration et gestion de la due diligence<\/em> ; <\/li>\n\n\n\n
  • Conduite des n\u00e9gociations sur les prix ;<\/li>\n\n\n\n
  • Assistance dans les n\u00e9gociations relatives \u00e0 la documentation juridique ;<\/li>\n\n\n\n
  • Coordination de toutes les parties impliqu\u00e9es, y compris les conseils juridiques et fiscaux.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    Investec a conseill\u00e9 les propri\u00e9taires de la clinique d’oncologie KHO (Klinik f\u00fcr H\u00e4matologie und Onkologie Hirslanden Z\u00fcrich) et de l’Onkozentrum…<\/p>\n","protected":false},"featured_media":0,"template":"","dt":[],"sector":[3768],"dealtype":[3706],"clienttype":[3729],"class_list":["post-56054","deals","type-deals","status-publish","hentry","sector-healthcare-fr","dealtype-cession-fr","clienttype-entrepreneurs-fr"],"acf":[],"yoast_head":"\nCession d'un groupe suisse leader en oncologie \u00e0 Hirslanden | Investec Business Advisory<\/title>\n<meta name=\"description\" content=\"Investec a conseill\u00e9 les propri\u00e9taires de la clinique KHO et de l'Onkozentrum \u00e0 Zurich dans le cadre de leur cession \u00e0 Hirslanden.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cession d'un groupe suisse leader en oncologie \u00e0 Hirslanden | Investec Business Advisory\" \/>\n<meta property=\"og:description\" content=\"Investec a conseill\u00e9 les propri\u00e9taires de la clinique KHO et de l'Onkozentrum \u00e0 Zurich dans le cadre de leur cession \u00e0 Hirslanden.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/\" \/>\n<meta property=\"og:site_name\" content=\"Investec Business Advisory\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T16:55:18+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/deals\\\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\\\/\",\"url\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/deals\\\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\\\/\",\"name\":\"Cession d'un groupe suisse leader en oncologie \u00e0 Hirslanden | Investec Business Advisory\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/#website\"},\"datePublished\":\"2026-01-12T09:35:13+00:00\",\"dateModified\":\"2026-01-12T16:55:18+00:00\",\"description\":\"Investec a conseill\u00e9 les propri\u00e9taires de la clinique KHO et de l'Onkozentrum \u00e0 Zurich dans le cadre de leur cession \u00e0 Hirslanden.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/deals\\\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/deals\\\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/deals\\\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cession d’un groupe suisse leader en oncologie \u00e0 Hirslanden\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/\",\"name\":\"Investec Business Advisory\",\"description\":\"Investec Business Advisory\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/#organization\",\"name\":\"Capitalmind Investec\",\"url\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/Logo_Investec_cmjn_6.jpg\",\"contentUrl\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/Logo_Investec_cmjn_6.jpg\",\"width\":1120,\"height\":1121,\"caption\":\"Capitalmind Investec\"},\"image\":{\"@id\":\"https:\\\/\\\/www.investec.com\\\/advisory\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/capitalmind---corporate-finance-advisory\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC4bVt7iNejh8tGT6Qfa9R4w\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cession d'un groupe suisse leader en oncologie \u00e0 Hirslanden | Investec Business Advisory","description":"Investec a conseill\u00e9 les propri\u00e9taires de la clinique KHO et de l'Onkozentrum \u00e0 Zurich dans le cadre de leur cession \u00e0 Hirslanden.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/","og_locale":"fr_FR","og_type":"article","og_title":"Cession d'un groupe suisse leader en oncologie \u00e0 Hirslanden | Investec Business Advisory","og_description":"Investec a conseill\u00e9 les propri\u00e9taires de la clinique KHO et de l'Onkozentrum \u00e0 Zurich dans le cadre de leur cession \u00e0 Hirslanden.","og_url":"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/","og_site_name":"Investec Business Advisory","article_modified_time":"2026-01-12T16:55:18+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/","url":"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/","name":"Cession d'un groupe suisse leader en oncologie \u00e0 Hirslanden | Investec Business Advisory","isPartOf":{"@id":"https:\/\/www.investec.com\/advisory\/fr\/#website"},"datePublished":"2026-01-12T09:35:13+00:00","dateModified":"2026-01-12T16:55:18+00:00","description":"Investec a conseill\u00e9 les propri\u00e9taires de la clinique KHO et de l'Onkozentrum \u00e0 Zurich dans le cadre de leur cession \u00e0 Hirslanden.","breadcrumb":{"@id":"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.investec.com\/advisory\/fr\/deals\/cession-groupe-suisse-leader-en-oncologie-a-hirslanden\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.investec.com\/advisory\/fr\/"},{"@type":"ListItem","position":2,"name":"Cession d’un groupe suisse leader en oncologie \u00e0 Hirslanden"}]},{"@type":"WebSite","@id":"https:\/\/www.investec.com\/advisory\/fr\/#website","url":"https:\/\/www.investec.com\/advisory\/fr\/","name":"Investec Business Advisory","description":"Investec Business Advisory","publisher":{"@id":"https:\/\/www.investec.com\/advisory\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.investec.com\/advisory\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.investec.com\/advisory\/fr\/#organization","name":"Capitalmind Investec","url":"https:\/\/www.investec.com\/advisory\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.investec.com\/advisory\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.investec.com\/advisory\/wp-content\/uploads\/2020\/01\/Logo_Investec_cmjn_6.jpg","contentUrl":"https:\/\/www.investec.com\/advisory\/wp-content\/uploads\/2020\/01\/Logo_Investec_cmjn_6.jpg","width":1120,"height":1121,"caption":"Capitalmind Investec"},"image":{"@id":"https:\/\/www.investec.com\/advisory\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/capitalmind---corporate-finance-advisory","https:\/\/www.youtube.com\/channel\/UC4bVt7iNejh8tGT6Qfa9R4w"]}]}},"_links":{"self":[{"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/deals\/56054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/deals"}],"about":[{"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/types\/deals"}],"wp:attachment":[{"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/media?parent=56054"}],"wp:term":[{"taxonomy":"dt","embeddable":true,"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/dt?post=56054"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/sector?post=56054"},{"taxonomy":"dealtype","embeddable":true,"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/dealtype?post=56054"},{"taxonomy":"clienttype","embeddable":true,"href":"https:\/\/www.investec.com\/advisory\/fr\/wp-json\/wp\/v2\/clienttype?post=56054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}